Cover Image

Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial

Background - The CAO/ARO/AIO trial has shown that oxaliplatin added to preoperative chemoradiotherapy and postoperative chemotherapy significantly improved disease-free survival in locally advanced rectal cancer (LARC). Here, we present a post-hoc analysis of quality of life (QoL) in disease-free pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Kosmala, Rebekka (Author) , Fokas, Emmanouil (Author) , Flentje, Michael (Author) , Sauer, Rolf (Author) , Liersch, Torsten (Author) , Graeven, Ullrich (Author) , Fietkau, Rainer (Author) , Hohenberger, Werner (Author) , Arnold, Dirk (Author) , Hofheinz, Ralf-Dieter (Author) , Ghadimi, Michael (Author) , Ströbel, Philipp (Author) , Staib, Ludger (Author) , Grabenbauer, Gerhard G. (Author) , Folprecht, Gunnar (Author) , Kirste, Simon (Author) , Uter, Wolfgang (Author) , Gall, Christine (Author) , Rödel, Claus (Author) , Polat, Bülent (Author)
Format: Article (Journal)
Language:English
Published: February 2021
In: European journal of cancer
Year: 2021, Volume: 144, Pages: 281-290
ISSN:1879-0852
DOI:10.1016/j.ejca.2020.11.029
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2020.11.029
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804920313666
Get full text
Author Notes:Rebekka Kosmala, Emmanouil Fokas, Michael Flentje, Rolf Sauer, Torsten Liersch, Ullrich Graeven, Rainer Fietkau, Werner Hohenberger, Dirk Arnold, Ralf-Dieter Hofheinz, Michael Ghadimi, Philipp Ströbel, Ludger Staib, Gerhard G. Grabenbauer, Gunnar Folprecht, Simon Kirste, Wolfgang Uter, Christine Gall, Claus Rödel, Bülent Polat
Description
Summary:Background - The CAO/ARO/AIO trial has shown that oxaliplatin added to preoperative chemoradiotherapy and postoperative chemotherapy significantly improved disease-free survival in locally advanced rectal cancer (LARC). Here, we present a post-hoc analysis of quality of life (QoL) in disease-free patients. - Patients and methods - Between 2006 and 2010, 1236 patients with LARC were randomly assigned either to preoperative chemoradiotherapy followed by total mesorectal excision and postoperative chemotherapy (N = 623) or combined with oxaliplatin (N = 613). QoL questionnaires (EORTC QLQ-C30, colorectal module CR38) were completed at baseline, after postoperative chemotherapy and during follow-up. Analysis was performed according intent-to-treat. - Results - Available questionnaires (baseline) were 82% (N = 512) in the control and 84% (N = 513) in the investigational group. Response rates were 49% (533 of 1086) at 1 year and 43% (403 of 928) at 3 years. Global health status (GHS) for disease-free patients was stable in both groups (range 0-100). At baseline: standard arm 62.0 (mean, SD 21.6; N = 491) versus oxaliplatin arm 63.2 (mean, SD 22; N = 503); at 3 years: 69.4 (SD 19.3; N = 187) versus 65.4 (SD 22.2; N = 202). After treatment and at 3 years, no significant differences (≥10 points) between groups were found in QoL subscales. Disease-free patients experiencing neurotoxic side-effects (grade 1-4) showed reduced GHS at 3 years versus patients without neurotoxicity (mean 59.2 versus 69.3; P < 0.001), while grade 3-4 rate was low. - Conclusion - The addition of oxaliplatin was not associated with worse overall QoL. This information is of interest to patients in many ongoing rectal cancer trials. - Trial registration information - NCT00349076.
Item Description:Gesehen am 14.04.2021
Physical Description:Online Resource
ISSN:1879-0852
DOI:10.1016/j.ejca.2020.11.029

Similar Items